Solicitation
Department of War Pharmacy Uniform Formulary Blanket Purchase Agreement / Uniform Formulary Additional Discount Program
Dept of Defense · Defense Health Agency (DHA) · Sol. HT9402-26-Q-9404
Due in 15 days
Track this notice by email. We'll email you if it's amended or awarded, and a week and two days before responses are due.
AI summary Beta
Some details weren't available to this summary, so it may miss requirements. Check the attachments on SAM.gov.
The Defense Health Agency is asking drug manufacturers to quote discounted prices and refunds on 12 newly FDA-approved brand drugs so its Pharmacy and Therapeutics Committee can decide where each drug sits on the military's Uniform Formulary (the list of covered drugs). Winning quotes can become Blanket Purchase Agreements for military hospitals and mail order, and refund agreements for the TRICARE retail pharmacy network. This is a pharmaceutical manufacturer program, not a general contract for services or supplies, and quotes are due October 26, 2026.
Watch out for
- Only for drug manufacturers. The quote forms, FSS requirement, NDC price lists and refund terms are all written for pharmaceutical makers of the 12 named drugs, so a typical small business reseller or services firm cannot take part.
The Company must have an existing FSS contract
- No guaranteed sales. Signing an agreement does not guarantee orders; the government only buys what is actually dispensed, and only if the drug is placed on the formulary.
obligation on the DOW to purchase any product.
- Price and refund commitments. Prices cannot rise above the quote for at least a year, and the government can end a BPA if FSS or Big 4 prices drop below it; ADP refunds are billed quarterly and late payment can end the agreement and trigger formulary reconsideration.
payment due seventy (70) days from the date the utilization data is made available
- Short deadline. Quotes are due October 26, 2026, and exception requests must reach the Contracting Officer at least 14 calendar days earlier.
- Quote hold period. The quote has to stay open for 180 days, so pricing must be committed well before the formulary decision.
agrees to hold its UF BPA price quote valid for 180 days.
Read from the notice and 4 attachments. 12 not read in full.
- A-3 RFQ HT9402-26-Q-9404 NAD.pdf
- FAR 52-225-6-Certificate.pdf
- DoD Formulary Placement of FDA Newly Approved Drugs.pdf
- Price Appendix FAQ NAD.pdf
- A-3 Price List_Adquey-Atopic-Topical Agents.xlsx: spreadsheet: not read yet
- A-3 Price List_Armlupeg-White Blood Cell Stim-Pegfilgrastims.xlsx: spreadsheet: not read yet
- A-3 Price List - Beqalzi - Onc Agents - Non-BTKI CLL-SLP.xlsx: spreadsheet: not read yet
- A-3 Price List_Bixlenvo-Antiretrovirals-Combinations.xlsx: spreadsheet: not read yet
- A-3 Price List_Clotic-Antifungals-NA.xlsx: spreadsheet: not read yet
- A-3 Price List_Etcamah-Breast Canc Agt-Estrogen Recptr Antag.xlsx: spreadsheet: not read yet
- A-3 Price List_Langlara-Insulins-Basal.xlsx: spreadsheet: not read yet
- A-3 Price List_Lisraya - TIBs - NA.xlsx: spreadsheet: not read yet
- A-3 Price List - Mimrylo - Hematological Agents - NA.xlsx: spreadsheet: not read yet
- A-3 Price List - Nuzolvence -Antibiotics - NA.xlsx: spreadsheet: not read yet
- A-3 Price List_Rasonque-Oncological Agents-RAS Inhibitors.xlsx: spreadsheet: not read yet
- A-3 Price List - Rezenopy - Alcohol Deterrents-Narcotic Antag.xlsx: spreadsheet: not read yet
Full brief
What they want
- UF BPA price quotes (Blanket Purchase Agreement prices) for military treatment facilities and TRICARE Mail Order Pharmacy, covering every NDC-11 package on the manufacturer's Federal Supply Schedule contract
- UF ADP refund quotes (Additional Discount Program) for drugs dispensed through the TRICARE retail pharmacy network, stated as a percentage of non-FAMP
- A completed NDC Price List (Excel) for each quoted drug, with price per unit and price per package
- Written answers to seven clinical questions about each newly approved drug, sent by email instead of a clinical presentation
- Signed quote forms, the quote submission checklist and the FAR 52.225-6 Trade Agreements Certificate
- Drugs under review: Adquey, Armlupeg, Beqalzi, Bixlenvo, Clotic, Etcamah, Langlara, Lisraya, Mimrylo, Nuzolvence, Rasonque and Rezenopy
- Contract type
- Request for quotation leading to Uniform Formulary Blanket Purchase Agreements (UF BPA) and Uniform Formulary Additional Discount Program refund agreements (UF ADP); no purchase obligation
- Period of performance
- No fixed term: quotes are held open 180 days; prices must stay at or below the quoted level for at least one calendar year; each agreement continues until the drug class is reevaluated or either side ends it with 120 days written notice
- Place of performance
- Defense Health Agency, San Antonio, TX (contracting office); prices apply to military treatment facilities, TRICARE mail order and the TRICARE retail pharmacy network
- Contract vehicle
- Quoter must already hold a Federal Supply Schedule (FSS) contract or FSS Interim Agreement for the quoted drug
- How they'll choose
- Not a standard price competition: the Pharmacy and Therapeutics Committee weighs each drug's clinical effectiveness and cost effectiveness, using the BPA price quote and ADP refund quote as the cost input, then recommends its formulary tier; the DHA Director makes the final decision
- Offers due
- October 26, 2026, 12:00 PM Central per the SAM.gov notice; the RFQ text mentions 12:00 PM CST for BPA quotes and 1:00 PM CST for ADP quotes, but its date table is blank in the text provided
- How to submit
- Email the original signed quote and NDC Price List to the RFQ Point of Contact listed in Part 2.3.1 of the RFQ
What they'll judge offers on
- Relative clinical effectiveness of the drug
- Relative cost effectiveness, using the UF BPA price (military facilities and mail order) and the UF ADP total retail refund
- Where no BPA quote is given, the lower of the Big 4 price or FSS price is used for evaluation
What to include when you submit
- Download the utilization dataset and NDC Price List from the DoW P&T committee website (health.mil/PandT) before quoting
- Submit a separate signed UF BPA (Appendix 2, pages 12-18) for each drug quoted and a signed UF ADP (Appendix 3, pages 19-25) for retail refund quotes
- Include the Manufacturer Quote Submission Checklist (Appendix 1) and the FAR 52.225-6 Trade Agreements Certificate
- Include the NDC Price List as an Excel file; price per unit to four decimal places and package price equal to unit price times package size
- Quote the same price per unit for every package size, and include all NDCs on the FSS contract unless an exclusion was approved in writing in advance
- Send exception or exclusion requests to the Contracting Officer at least 14 calendar days before the quote due date
- Email answers to the seven clinical questions in Part 3.4 to the RFQ POC
- Register for the pre-quotation teleconference on October 14, 2026 by emailing the RFQ POC with participant name, company and any advance questions
You must have
- Existing Federal Supply Schedule contract or FSS Interim Agreement covering each quoted drug when the BPA is signed
The Company must have an existing FSS contract
- Active SAM registration when the quote is submitted, kept active through the agreement
Offerors are required to be registered in SAM at the time the quotation is
- Trade Agreements Act compliant drug and NDCs, with a completed FAR 52.225-6 certificate
Confirm that the drug and any relevant NDCs are considered Trade Agreement Act
- Agree to work with the DoW Prime Vendor Program (required to take part in the BPA)
Company agrees to work with DOW Prime Vendor Program for both MTF and mail
- Quoted BPA prices must be equal to or lower than the company's FSS, Big 4 and Joint National Contract prices
Verify quoted prices are equal to or lower than company
- For ADP quotes, the drug must first be on a DoW Retail Refunds Pricing Agreement, and the company must agree to open limited distribution to Accredo for TRICARE mail order
Not in the notice text
- The RFQ dates table (posting date, quotes due, P&T meeting date, due date for clinical question responses) did not come through in the text, so only the notice's October 26, 2026 due date and October 14, 2026 teleconference date are confirmed
- The twelve drug-specific NDC price list spreadsheets were not read, so the exact NDCs, condition sets and formulary notes are not known
- Which email address belongs to the RFQ POC versus the P&T Committee POC and Industry Technical Liaison is not clear in the text
- No dollar value or expected volume is stated; historical utilization is only in a separate dataset on the P&T website
Is this a fit for your business?
Create a free accountFedReady checks notices like this against your business profile, tracks deadlines, and alerts you to new matches. Creating an account is free.
Key facts
- Response due
- Oct 26, 2026, 5:00 PM UTC
- Posted
- Oct 8, 2026
- Notice type
- Solicitation
- Solicitation
- HT9402-26-Q-9404
- Agency
- Dept of Defense · Defense Health Agency (DHA)
- Office
- Defense Health Agency (DHA)
- Set-aside
- No Set aside used
- NAICS
- 325412
- Product/service code
- 6505
- Business type
- Medical & healthcare
- Place of performance
- San Antonio, TX, 78230
- Contracting contact
- Tracy Bankstracy.e.banks2.civ@health.mil
What similar contracts paid
145 contracts at this agency for the same NAICS and product/service codes had activity in the last 5 years, according to USAspending.gov. Small businesses won 17% of the dollars in this market over the last 3 fiscal years.
Typical contract$129KMiddle half: $25.3K to $249K
Typical per year$104KValue divided by years of performance
Before you respond
Full notice text from SAM.gov
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Adquey - Atopic - Subclass: Topical Agents b. Armlupeg - White Blood Cell Stimulants - Subclass: Pegfilgrastims c. Beqalzi - Oncological Agents - Non-BTKI for Chronic Lymphocytic Leukemia-Small Lymphocytic Lymphoma d. Bixlenvo - Antiretrovirals - Subclass: Combinations e. Clotic - Antifungals - Subclass: NA f. Etcamah - Breast Cancer Agents - Estrogen Receptor Antagonist g. Langlara - Insulins - Subclass: Basal h. Lisraya - Targeted Immunomodulatory Biologics – NA i. Mimrylo - Hematological Agents – NA j. Nuzolvence - Antibiotics – NA k. Rasonque - Oncological Agents - Subclass: RAS Inhibitors l. Rezenopy - Alcohol Deterrants - Narcotic Antagonists The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9404. Pre-quotation teleconference is on October 14, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
Similar open opportunities
- Febuxostat TabletsDLA Troop Support wants one national supplier of febuxostat tablets (40 mg and 80 mg, 30-count bottles) for the DoD and VA pharmacy prime vendor programs.
- Latanoprost Ophthalmic Solution (VA-27-00006027)The VA Enterprise Procurement Office plans to buy Latanoprost eye drops (an ophthalmic solution) for VA, DoD, Bureau of Prisons, Indian Health Service and the Federal Health Care…
- Imatinib TabletsThe Department of Veterans Affairs (National Acquisition Center) plans to award one contract for imatinib mesylate tablets, a cancer drug, to supply VA, DoD, Bureau of Prisons,…
- Methylphenidate ERThe Defense Logistics Agency (DLA Troop Support) plans a national requirements contract for Methylphenidate ER tablets (18, 27, 36 and 54 mg, 100-count bottles).
- Epinephrine InjectorThe Defense Logistics Agency (DLA Troop Support) wants one national supplier of Epinephrine 0.3 mg/0.3 mL auto-injectors (2-count boxes) for DoD, VA, Indian Health Service and…